Biophytis Announces An Exclusive License Agreement With Blanver For BIO101 (20-hydroxyecdysone) In Latin American, Biophytis Will Be Able To Receive Up To €108M Including An Upfront Payment And Further Additional Milestone Payments
Biophytis Announces An Exclusive License Agreement With Blanver For BIO101 (20-hydroxyecdysone) In Latin American, Biophytis Will Be Able To Receive Up To €108M Including An Upfront Payment And Further Additional Milestone Payments
The agreement provides that Blanver will be responsible for the registration, marketing and commercialization of BIO 101 (20-Hydroxyecdysone) in its various indications: obesity, respiratory infections due to Covid-19, sarcopenia and Duchenne Muscular Dystrophy (DMD) - once Biophytis has successfully completed the planned clinical development programmes for its drug candidate. With 40 years of history, Blanver has become an expert in infectious diseases, osteoporosis and metabolic disorders, which is a perfect match with Biophytis. In addition of Brazil, Blanver has an extensive network of unique distributors that covers the whole Latin America region.
协议规定，一旦Biophytis成功完成其药物候选的计划临床开发项目，Blanver将负责BIO 101（20-Hydroxyecdysone）在其各种适应症（包括肥胖症，由Covid-19引起的呼吸系统感染，肌无力症和杜兴肌肉萎缩症）的注册，营销和商业化。拥有40年历史的Blanver已成为传染病，骨质疏松症和代谢性疾病的专家，这与Biophytis非常相配。除了巴西，Blanver还拥有一个广泛的独特分销网络，覆盖整个拉丁美洲地域板块。